BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7969222)

  • 1. P53 and mdm-2: interactions between tumor suppressor gene and oncogene products.
    Perry ME; Levine AJ
    Mt Sinai J Med; 1994 Sep; 61(4):291-9. PubMed ID: 7969222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
    Zietz C; Rössle M; Haas C; Sendelhofert A; Hirschmann A; Stürzl M; Löhrs U
    Am J Pathol; 1998 Nov; 153(5):1425-33. PubMed ID: 9811333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations and MDM-2 amplification in renal cell cancers.
    Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
    Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The regulation of p53-mediated transcription and the roles of hTAFII31 and mdm-2.
    Lu H; Lin J; Chen J; Levine AJ
    Harvey Lect; 1994-1995; 90():81-93. PubMed ID: 8803320
    [No Abstract]   [Full Text] [Related]  

  • 6. Mdm-2: "big brother" of p53.
    Momand J; Zambetti GP
    J Cell Biochem; 1997 Mar; 64(3):343-52. PubMed ID: 9057092
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
    Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
    Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
    Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
    Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 and mdm-2 genes in human testicular germ-cell tumors.
    Riou G; Barrois M; Prost S; Terrier MJ; Theodore C; Levine AJ
    Mol Carcinog; 1995 Mar; 12(3):124-31. PubMed ID: 7893365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas.
    Waber PG; Chen J; Nisen PD
    Cancer Res; 1993 Dec; 53(24):6028-30. PubMed ID: 8261417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting the p53 pathway for cancer diagnosis and therapy.
    Lane DP
    Br J Cancer; 1999 Jul; 80 Suppl 1():1-5. PubMed ID: 10466753
    [No Abstract]   [Full Text] [Related]  

  • 12. Amplification of a gene encoding a p53-associated protein in human sarcomas.
    Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B
    Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
    Cheng YT; Li YL; Wu JD; Long SB; Tzai TS; Tzeng CC; Lai MD
    Mol Carcinog; 1995 Jul; 13(3):173-81. PubMed ID: 7619220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics].
    Marine Ch
    Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters.
    Okita S; Tsutsumi M; Onji M; Konishi Y
    Mol Carcinog; 1995 Aug; 13(4):266-71. PubMed ID: 7646765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
    Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
    Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers.
    Hollstein M; Marion MJ; Lehman T; Welsh J; Harris CC; Martel-Planche G; Kusters I; Montesano R
    Carcinogenesis; 1994 Jan; 15(1):1-3. PubMed ID: 8293534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for manipulating the p53 pathway in the treatment of human cancer.
    Hupp TR; Lane DP; Ball KL
    Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.
    Juven T; Barak Y; Zauberman A; George DL; Oren M
    Oncogene; 1993 Dec; 8(12):3411-6. PubMed ID: 8247544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas.
    Chang KW; Laconi S; Mangold KA; Hubchak S; Scarpelli DG
    Cancer Res; 1995 Jun; 55(12):2560-8. PubMed ID: 7780969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.